NEW YORK (GenomeWeb) – Agilent Technologies said that CEO William Sullivan will step down from that role on March 18, 2015, and serve as an advisor to the firm through its fiscal year ending Oct. 31, 2015. Sullivan will be succeeded by Mike McMullen, currently Agilent SVP and president of the company's Chemical Analysis Group. McMullen also was immediately named president and COO of the company in the first step of the transition. He joined Agilent's predecessor company Hewlett-Packard in 1984 as a financial analyst in its Analytical Products Group, and has since held various senior management positions as Agilent.
Agilent also has appointed Alessandro Borsatti to senior director of product marketing and scientific affairs. He has had various roles at Agilent since joining the company in February 2013. Before that, he was global business director of molecular diagnostics at PerkinElmer.
In addition, the firm has appointed Rebecca Brandes its new global marketing director of molecular pathology. She is a co-founder of Prairie Fire Labs and was also the owner and executive vice president of sales and marketing at i.d.i consulting and Celerity Marketing Group.
Nabsys has appointed Steve Lombardi to president, CEO, and to its board of directors. Previously, he was CEO of Real Time Genomics, and before that he was CEO of Helicos BioSciences. He has also served as senior vice president of Affymetrix and vice president of genetic analysis at Applied Biosystems.
Thermo Fisher Scientific has appointed Andrea Califano, Arnold Levine, and Aviv Regev to its scientific advisory board.
Califano is founding chairman of the department of systems biology at Columbia University and he currently serves on the board of scientific advisors at the National Cancer Institute.
Levine is professor emeritus of systems biology at the Institute for Advanced Study and professor of pediatrics and of biochemistry with the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey.
Regev is a core member of the Broad Institute and an associate professor of biology at the Massachusetts Institute of Technology. She is also an investigator at the Howard Hughes Medical Institute.
Meridian Bioscience Founder and Executive Chairman of the Board William Motto has died, the company said in a filing with the US Securities and Exchange Commission this week. Meridian said its board has elected company CEO John Kraeutler to serve as chairman of the board.
The US Food and Drug Administration has promoted Grail Sipes as its permanent director of the Office of Regulatory Policy (ORP). Sipes bring two decades of experience as a lawyer to the new position that she will assume on Sept. 22.
Sipes joined FDA's Center for Drug Evaluation and Research in 2011 as senior regulatory counsel for ORP. Before that Grail was a partner with Covington & Burling, where she was part of the Food and Drug Practice Group, as well as the Life Sciences Industry Group.
Adaptive Biotechnologies has appointed Brian Hansen as its chief commercial officer, responsible for overseeing the firm's sales, customer relations, marketing, billing, and reimbursement efforts. Hansen joins Adaptive from Novartis subsidiary Genoptix, where he was senior VP of global sales and service.
Trovagene has appointed cancer genetics pioneer Alberto Bardelli to its scientific advisory board. Bardelli was among the first researchers to identify mutations in kinase genes linked to colorectal cancer and other tumors. Currently, Bardelli is director of the Laboratory of Molecular Genetics at the Institute for Cancer Research and Treatment and an associate professor in the oncology department at the Torino Medical School in Candiolo, Italy. He also cofounded the biotechnology firm Horizon Discovery Group.
Veracyte has promoted Christopher Hall to COO, the company announced. Hall joined the firm in 2010 as chief commercial officer.
GNS Healthcare has tapped Jan Berger to serve on its board of directors.
Berger is currently president and CEO of Health Intelligence Partners, a consultancy that provides business strategies and solution. She has also served as CVS Caremark's chief clinical officer, among other positions.
Mt. Sinai is launching a new genetic testing laboratory in Branford, Conn., and has hired Todd Arnold to serve as the lab's managing director and Daniel Sisco to serve as director of laboratory operations.
Arnold was most recently vice president of research and development in Roche's 454 Life Sciences division, where he held several other positions. Before that, he was director of applications support, research and development at CUNO. He was also manager of DNA chemistry at Gamera Bioscience and a molecular biologist at Millipore.
Sisco was most recently director of Roche's 454 sequencing center. Before joining 454, he was a research specialist at EnGenCore.
Quanterix has named Mark Roskey VP and general manager of Applications and Reagents. In the role, he will be responsible for the development and expansion of key application areas using the company's Simoa platform, including assay development and an internal lab that provides customer evaluations and service offerings.
Roskey previously was VP and GM of PerkinElmer's Life Science and Technology division's American Sales and Service organization. He also formerly held senior commercial and technical positions at Caliper Life Sciences, and he has more than 25 years of experience in the life sciences industries.
The Personalized Medicine Coalition announced that Daryl Pritchard will be its new VP of science policy, in charge of promoting the organization's science-related policies and of raising awareness of precision healthcare issues among policymakers, providers, and patients.
Before joining PMC, Pritchard was director of policy research at the National Pharmaceutical Council; director of research programs advocacy and personalized medicine at the Biotechnology Industry Organization; and the director of government affairs for the American Association for Dental Research.
CombiMatrix disclosed in a filing with the US Securities and Exchange Commission that Wei Richard Ding has tendered his resignation as a member of the firm's board of directors. It said Ding is pursuing a career opportunity that will relocate him overseas.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.